Identity
Lactoferrin is an iron-binding glycoprotein of the transferrin family — roughly 80 kDa, around 690 amino acids, with two lobes each capable of binding a ferric iron ion. It occurs naturally in milk (highest in colostrum), and in saliva, tears, nasal secretions and the granules of neutrophils, where it forms part of innate immune defence. Commercially it comes in two forms that matter for reading the evidence: bovine lactoferrin (bLF), purified from cow's milk, which is what almost every clinical trial has used; and recombinant human lactoferrin (rhLF), produced in engineered expression systems, which is newer and has a much smaller evidence base of its own.
Development & history
- 1939: Identified in bovine milk; characterised properly in the 1960s, when its iron-binding role and abundance in human colostrum became clear.
- 1970s–1990s: Mechanistic work established the two arms of its activity — iron sequestration (depriving bacteria of the free iron they need) and direct antimicrobial action of the N-terminal fragment lactoferricin, alongside immunomodulatory effects.
- 1990s–2000s: Industrial purification from whey made bovine lactoferrin commercially viable; adoption into infant formula followed, with regulatory novel-food and GRAS clearances.
- 2010s: The clinical evidence base built in two directions: neonatal and paediatric infection prevention (culminating in Cochrane review CD007137 and the trials it pooled), and iron-deficiency anaemia, where the argument was never that lactoferrin beats iron but that it matches it with far better gastrointestinal tolerability.
- 2017: The acne trial (Chan et al.) — a properly randomised, placebo-controlled, 164-participant study — put lactoferrin on the skincare map, though it tested a lactoferrin-vitamin-E-zinc combination rather than lactoferrin alone.
- 2020s: Recombinant human lactoferrin entered the market with its own safety and GRAS work; a 2025 randomised trial compared it to bovine lactoferrin on safety and antibody endpoints. A 2025 meta-analysis (Mayorga et al.) consolidated the paediatric infection evidence.
Mechanism (as proposed)
Lactoferrin's activity rests on three overlapping properties. First, iron sequestration: by binding free iron with high affinity, it deprives iron-dependent bacteria of a nutrient they need, which is the classical explanation for its antimicrobial effect — and, paradoxically, the same property underlies its use in iron deficiency, since lactoferrin appears to deliver iron through a receptor-mediated route that bypasses the gut irritation caused by free ferrous iron. Second, direct antimicrobial action: the N-terminal region (and the derived peptide lactoferricin) disrupts bacterial membranes independently of iron binding. Third, immunomodulation: lactoferrin interacts with immune cell receptors and influences cytokine signalling, which is the proposed basis for its effects on inflammation.
For skin specifically, the proposed route in the acne work is a combination of reduced sebum production (shown at cell and mouse level) and dampened inflammatory signalling around the sebaceous unit. That mechanism is coherent, and it is the part the topical products lean on — but mechanism at cell level and clinical benefit on human skin are, as always, separate claims with separate evidence.
Reading the evidence honestly
Lactoferrin is a case where the underlying science is genuinely good and the consumer marketing still outruns it, in three specific ways worth naming.
The strong evidence is population-specific. The A-grade findings here — neonatal sepsis, childhood diarrhoea — come from preterm infants and young children, often in high-infection-burden settings. Those are real, meta-analysis-backed results. They are not a basis for claims about immune support in a healthy adult buying a supplement, and translating them across is the most common misuse of this ingredient's evidence.
The acne result is a combination result. The 2017 trial is a good trial, and its numbers are respectable. But it tested lactoferrin with vitamin E and zinc, and zinc has independent evidence in acne. Any product or article presenting that trial as proof that lactoferrin fades acne is attributing a combination's effect to one component — a textbook outcome substitution.
The "immune" study measured antibodies, not immunity. The 2025 recombinant lactoferrin trial is frequently cited as clinical validation. Its primary endpoint was change in anti-lactoferrin antibody levels — an immunogenicity and safety question. It shows the ingredient is well tolerated and doesn't disturb iron metabolism. It does not show it improves immune function, because that is not what it asked.
Add the fact that nearly all efficacy evidence used bovine lactoferrin while the premium marketing increasingly features recombinant human lactoferrin, and the honest summary is: a well-tolerated, genuinely evidenced protein in specific clinical settings, with a plausible but under-tested skin story, sold on a general-wellness promise the trials were never designed to support.